Trial Profile
Influence of XOI, Febuxostat, on Vascular Function in Patients with Hyperuricemia and Cardiovascular Risk Factors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2019
Price :
$35
*
At a glance
- Drugs Febuxostat (Primary) ; Allopurinol
- Indications Aortic dissection; Cerebrovascular disorders; Diabetes mellitus; Dyslipidaemias; Hypertension; Hyperuricaemia; Ischaemic heart disorders; Metabolic syndrome; Renal impairment
- Focus Pharmacodynamics
- Acronyms J-XOI study
- 20 Mar 2019 Status changed from active, no longer recruiting to completed.
- 07 May 2018 Status changed from recruiting to active, no longer recruiting.
- 03 Nov 2015 New trial record